Halozyme Therapeutics reported $136.45M in Sales Revenues for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Acadia Pharmaceuticals ACAD:US $ 115.22M 8.67M
Alnylam Pharmaceuticals ALNY:US $ 220.55M 42.99M
Amarin AMRN:US $ 154.49M 12.32M
Amgen AMGN:US $ 6526M 625M
Aptinyx Inc APTX:US $ 0 1000K
Arena Pharmaceuticals ARNA:US $ 0M 0M
Baxter International BAX:US $ 3098M 152M
Cara Therapeutics CARA:US $ 0 1.93M
Cytokinetics CYTK:US $ 2.84M 3.7M
Eli Lilly And LLY:US $ 6740.1M 65.5M
Esperion Therapeutics ESPR:US $ 40.66M 32.68M
Halozyme Therapeutics HALO:US $ 136.46M 47.43M
Immunogen IMGN:US $ 16.95M 1.24M
Intercept Pharmaceuticals ICPT:US $ 96.58M 14.92M
Intra Cellular Therapies ITCI:US $ 20.05M 4.17M
Intrexon XON:US $ 33.58M 9.07M
JAZZ PHA JAZZ:US $ 751.81M 144.23M
Mannkind MNKD:US $ 23.28M 5.84M
Nektar Therapeutics NKTR:US $ 28.33M 4.68M
Peregrine Pharmaceuticals PPHM:US $ 30.75M 3.15M
Pfizer PFE:US $ 18977M 4395M
Rigel Pharmaceuticals RIGL:US $ 26.27M 54.75M
United Therapeutics UTHR:US $ 446.5M 67.4M
Vanda Pharmaceuticals VNDA:US $ 67.9M 5.23M